Molecular Encapsulation of Abiraterone Acetate in 2,6 Di-O-Methyl-β-Cyclodextrin for Solubility Enhancement: Synthesis, Characterization, In Vitro Drug Release, and Molecular Docking-Reference-Cited by-同舟云学术

Molecular Encapsulation of Abiraterone Acetate in 2,6 Di-O-Methyl-β-Cyclodextrin for Solubility Enhancement: Synthesis, Characterization, In Vitro Drug Release, and Molecular Docking

Published:2024-08-02 Issue: Volume: Page:
ISSN:2191-1630
Container-title:BioNanoScience
language:en
Short-container-title:BioNanoSci.

Author:

Devangan Pawan^ORCID,Mourya Atul,Arya Shristi,Patel Digeshwari,Jaiswal Aman,Dewangan Atul

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12668-024-01579-7.pdf

Reference41 articles.

1. Harshman, L. C., & Taplin, M.-E. (2013). Abiraterone acetate: Targeting persistent androgen dependence in castration-resistant prostate cancer. Advances in Therapy, 30(8), 727–747. https://doi.org/10.1007/s12325-013-0050-3

2. Das, P., Taylor, S., Price, J., Jones, M., Martin-Fernandez, C., Ali, A., … Ward, C. (2020). Abiraterone acetate plus prednisone/prednisolone compared with enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES). BJUI Compass, 1(1), 21–31. https://doi.org/10.1002/bco2.11

3. Auchus, R. J., Yu, M. K., Nguyen, S., & Mundle, S. D. (2014). Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. The Oncologist, 19(12), 1231–1240. https://doi.org/10.1634/theoncologist.2014-0167

4. Scott, L. J. (2017). Abiraterone acetate: A review in metastatic castration-resistant prostrate cancer. Drugs, 77(14), 1565–1576. https://doi.org/10.1007/s40265-017-0799-9

5. Schultz, H. B., Meola, T. R., Thomas, N., & Prestidge, C. A. (2020). Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. International Journal of Pharmaceutics, 577, 119069. https://doi.org/10.1016/j.ijpharm.2020.119069